Literature DB >> 3129987

In vitro evaluation of josamycin, spiramycin, and erythromycin against Rickettsia rickettsii and R. conorii.

D Raoult1, P Roussellier, J Tamalet.   

Abstract

The antimicrobial activities of josamycin, erythromycin, and spiramycin against Rickettsia conorii and R. rickettsii were evaluated in two tests: a dye-uptake assay and a plaque assay. The MIC of josamycin was 1 microgram/ml for both species; the MICs of erythromycin and spiramycin were 4 to 8 and 16 to 32 micrograms/ml, respectively, for both species. Only josamycin may be of clinical use in treating spotted fever rickettsiosis. It may be useful in treating pregnant women and young children.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3129987      PMCID： PMC172145          DOI： 10.1128/AAC.32.2.255

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro antibiotic susceptibility of Rickettsia rickettsii and Rickettsia conorii: plaque assay and microplaque colorimetric assay.

Authors:  D Raoult; P Roussellier; G Vestris; J Tamalet
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

2.  In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay.

Authors:  D Raoult; P Roussellier; V Galicher; R Perez; J Tamalet
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

3.  Mediterranean spotted fever: clinical, laboratory and epidemiological features of 199 cases.

Authors:  D Raoult; P J Weiller; A Chagnon; H Chaudet; H Gallais; P Casanova
Journal:  Am J Trop Med Hyg       Date:  1986-07       Impact factor: 2.345

4.  [In vitro susceptibility of recent clinical isolates of Rickettsia tsutsugamushi to chemotherapeutic agents].

Authors:  S Miyamura; N Sato; A Tamura
Journal:  Kansenshogaku Zasshi       Date:  1985-05

5.  [Statement of the Antibiogram Committee of the French Microbiological Society].

Authors: 
Journal:  Pathol Biol (Paris)       Date:  1985-05

6.  Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases.

Authors:  C G Helmick; K W Bernard; L J D'Angelo
Journal:  J Infect Dis       Date:  1984-10       Impact factor: 5.226

7.  In vitro studies of the action of antibiotics on Rickettsia prowazeki by two basic methods of cell culture.

Authors:  C L Wisseman; A D Waddell; W T Walsh
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

8.  Susceptibility of Rickettsia conorii and R. rickettsii to pefloxacin, in vitro and in ovo.

Authors:  D Raoult; P Roussellier; G Vestris; V Galicher; R Perez; J Tamalet
Journal:  J Antimicrob Chemother       Date:  1987-03       Impact factor: 5.790

9.  Ciprofloxacin therapy for Mediterranean spotted fever.

Authors:  D Raoult; H Gallais; P De Micco; P Casanova
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191
  9 in total
  11 in total

Review 1.  Antimicrobial therapy of rickettsial diseases.

Authors:  D Raoult; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

2.  Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever.

Authors:  F Bella; B Font; S Uriz; T Muñoz; E Espejo; J Traveria; J A Serrano; F Segura
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  In vitro and in vivo antibiotic susceptibilities of ELB rickettsiae.

Authors:  S Radulovic; J A Higgins; D C Jaworski; A F Azad
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

4.  Randomized Trial of Clarithromycin for Mediterranean Spotted Fever.

Authors:  Esperança Anton; Tomas Muñoz; Francisco Javier Travería; Gemma Navarro; Bernat Font; Isabel Sanfeliu; Ferran Segura
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers.

Authors:  T J Ives; P Manzewitsch; R L Regnery; J D Butts; M Kebede
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

6.  Antibiotic susceptibility of rickettsia and treatment of rickettsioses.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

7.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  In vitro susceptibilities of Rickettsia rickettsii and Rickettsia conorii to roxithromycin and pristinamycin.

Authors:  M Drancourt; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

Review 9.  Antibiotic treatment of rickettsiosis, recent advances and current concepts.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

10.  In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin.

Authors:  D Raoult; P Bres; M Drancourt; G Vestris
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.